Elisabetta Giannotti1, Sarah Vinnicombe1, Kim Thomson2, Dennis McLean2, Colin Purdie3, Lee Jordan3, Andy Evans1. 1. 1 Division of Imaging and Technology, Medical Research Institute Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. 2. 2 Breast Imaging Department, Ninewells Hospital and Medical School, Dundee, UK. 3. 3 Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK.
Abstract
OBJECTIVE: To establish if palpable breast masses with benign greyscale ultrasound features that are soft on shear-wave elastography (SWE) (mean stiffness <50 kPa) have a low enough likelihood of malignancy to negate the need for biopsy or follow-up. METHODS: The study group comprised 694 lesions in 682 females (age range 17-95 years, mean age 56 years) presenting consecutively to our institution with palpable lesions corresponding to discrete masses at ultrasound. All underwent ultrasound, SWE and needle core biopsy. Static greyscale images were retrospectively assigned Breast Imaging Reporting and Data System (BI-RADS) scores by two readers blinded to the SWE and pathology findings, but aware of the patient's age. A mean stiffness of 50 kPa was used as the SWE cut-off for calling a lesion soft or stiff. Histological findings were used to establish ground truth. RESULTS: No cancer had benign characteristics on both modalities. 466 (99.8%) of the 467 cancers were classified BI-RADS 4a or above. The one malignant lesion classified as BI-RADS 3 was stiff on SWE. 446 (96%) of the 467 malignancies were stiff on SWE. No cancer in females under 40 years had benign SWE features. 74 (32.6%) of the 227 benign lesions were BI-RADS 3 and soft on SWE; so, biopsy could potentially have been avoided in this group. CONCLUSION: Lesions which appear benign on greyscale ultrasound and SWE do not require percutaneous biopsy or short-term follow-up, particularly in females under 40 years. ADVANCES IN KNOWLEDGE: None of the cancers had benign characteristics on both greyscale ultrasound and SWE, and 32% of benign lesions were BI-RADS 3 and soft on SWE; lesions that are benign on both ultrasound and SWE may not require percutaneous biopsy or short-term follow-up.
OBJECTIVE: To establish if palpable breast masses with benign greyscale ultrasound features that are soft on shear-wave elastography (SWE) (mean stiffness <50 kPa) have a low enough likelihood of malignancy to negate the need for biopsy or follow-up. METHODS: The study group comprised 694 lesions in 682 females (age range 17-95 years, mean age 56 years) presenting consecutively to our institution with palpable lesions corresponding to discrete masses at ultrasound. All underwent ultrasound, SWE and needle core biopsy. Static greyscale images were retrospectively assigned Breast Imaging Reporting and Data System (BI-RADS) scores by two readers blinded to the SWE and pathology findings, but aware of the patient's age. A mean stiffness of 50 kPa was used as the SWE cut-off for calling a lesion soft or stiff. Histological findings were used to establish ground truth. RESULTS: No cancer had benign characteristics on both modalities. 466 (99.8%) of the 467 cancers were classified BI-RADS 4a or above. The one malignant lesion classified as BI-RADS 3 was stiff on SWE. 446 (96%) of the 467 malignancies were stiff on SWE. No cancer in females under 40 years had benign SWE features. 74 (32.6%) of the 227 benign lesions were BI-RADS 3 and soft on SWE; so, biopsy could potentially have been avoided in this group. CONCLUSION: Lesions which appear benign on greyscale ultrasound and SWE do not require percutaneous biopsy or short-term follow-up, particularly in females under 40 years. ADVANCES IN KNOWLEDGE: None of the cancers had benign characteristics on both greyscale ultrasound and SWE, and 32% of benign lesions were BI-RADS 3 and soft on SWE; lesions that are benign on both ultrasound and SWE may not require percutaneous biopsy or short-term follow-up.
Authors: Wendie A Berg; David O Cosgrove; Caroline J Doré; Fritz K W Schäfer; William E Svensson; Regina J Hooley; Ralf Ohlinger; Ellen B Mendelson; Catherine Balu-Maestro; Martina Locatelli; Christophe Tourasse; Barbara C Cavanaugh; Valérie Juhan; A Thomas Stavros; Anne Tardivon; Joel Gay; Jean-Pierre Henry; Claude Cohen-Bacrie Journal: Radiology Date: 2012-02 Impact factor: 11.105
Authors: Andrew Evans; Patsy Whelehan; Kim Thomson; Denis McLean; Katrin Brauer; Colin Purdie; Lee Jordan; Lee Baker; Alastair Thompson Journal: Breast Cancer Res Date: 2010-12-01 Impact factor: 6.466
Authors: A Evans; P Whelehan; K Thomson; K Brauer; L Jordan; C Purdie; D McLean; L Baker; S Vinnicombe; A Thompson Journal: Br J Cancer Date: 2012-06-12 Impact factor: 7.640
Authors: A Evans; S Armstrong; P Whelehan; K Thomson; P Rauchhaus; C Purdie; L Jordan; L Jones; A Thompson; S Vinnicombe Journal: Br J Cancer Date: 2013-10-29 Impact factor: 7.640
Authors: Anton S Becker; Michael Mueller; Elina Stoffel; Magda Marcon; Soleen Ghafoor; Andreas Boss Journal: Br J Radiol Date: 2018-01-10 Impact factor: 3.039